Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
$2.39
+4.8%
$1.96
$1.33
$3.58
$112.59M0.7496,818 shs193,346 shs
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
$1.17
$1.31
$0.77
$2.63
$97.94M1.051.34 million shs1.35 million shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.98
+0.4%
$3.55
$2.57
$6.88
$24.59M0.642,828 shs1,379 shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$1.87
+7.5%
$1.69
$1.02
$6.23
$105.83M0.99254,039 shs353,254 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
0.00%+41.42%+20.10%+31.32%-5.16%
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
0.00%-10.69%-16.43%+6.36%-42.65%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%+3.52%+8.90%+18.66%-27.73%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.00%+3.89%0.00%+35.51%-68.25%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
3.0157 of 5 stars
3.55.00.00.02.51.70.0
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
2.5632 of 5 stars
3.72.00.00.03.90.00.6
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3.2845 of 5 stars
3.55.00.00.02.41.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
3.00
Buy$7.00192.89% Upside
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
3.33
Buy$8.00583.76% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3.00
Buy$7.80317.11% Upside

Current Analyst Ratings Breakdown

Latest NAII, TCRX, ADAG, and CRDL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/15/2025
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $7.00
8/12/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$7.00
8/6/2025
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/6/2025
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$7.00
6/2/2025
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
$100K1,125.93N/AN/A$0.80 per share2.99
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/AN/AN/AN/A$0.10 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$125.48M0.20N/AN/A$13.32 per share0.30
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$2.82M37.53N/AN/A$3.12 per share0.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
-$33.42MN/A0.00N/AN/AN/AN/AN/AN/A
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
-$26.77M-$0.34N/AN/AN/AN/A-232.26%-158.19%N/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/26/2025 (Estimated)
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$127.50M-$1.09N/AN/AN/A-1,964.88%-63.33%-40.19%11/11/2025 (Estimated)

Latest NAII, TCRX, ADAG, and CRDL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
-$0.11-$0.07+$0.04-$0.07N/AN/A
8/12/2025Q2 2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.28-$0.2848-$0.0048-$0.28$1.31 million$3.08 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
N/AN/AN/AN/AN/A
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
0.01
2.29
2.30
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
0.01
2.46
3.26
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.18
7.06
7.06

Institutional Ownership

CompanyInstitutional Ownership
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
9.51%
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
12.49%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
82.83%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
26047.11 million37.12 millionNot Optionable
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
2083.71 million79.32 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
10056.59 million54.13 millionNot Optionable

Recent News About These Companies

Lifesci Capital Issues Pessimistic Outlook for TCRX Earnings
Wedbush Cuts Earnings Estimates for TScan Therapeutics
HC Wainwright Expects Higher Earnings for TScan Therapeutics
Q3 EPS Estimates for TScan Therapeutics Cut by Wedbush
Research Analysts Set Expectations for TCRX Q3 Earnings
TScan Therapeutics Elects New Directors at Annual Meeting

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adagene stock logo

Adagene NASDAQ:ADAG

$2.39 +0.11 (+4.82%)
Closing price 08/22/2025 03:57 PM Eastern
Extended Trading
$2.42 +0.02 (+1.05%)
As of 08/22/2025 06:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Cardiol Therapeutics stock logo

Cardiol Therapeutics NASDAQ:CRDL

$1.17 0.00 (0.00%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.17 0.00 (-0.09%)
As of 08/22/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.95 -0.01 (-0.23%)
As of 08/22/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

TScan Therapeutics stock logo

TScan Therapeutics NASDAQ:TCRX

$1.87 +0.13 (+7.47%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.87 0.00 (0.00%)
As of 08/22/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.